• 1
    Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002; 81: 13953.
  • 2
    Carpentier PH, Maricq HR. Microvasculature in systemic sclerosis. Rheum Dis Clin North Am 1990; 16: 7591.
  • 3
    Lee P, Leung FY, Alderdice C, Armstrong SK. Nailfold capillary microscopy in the connective tissue diseases: a semiquantitative assessment. J Rheumatol 1983; 10: 9308.
  • 4
    Ingegnoli F, Boracchi P, Gualtierotti R, Lubatti C, Meani L, Zahalkova L, et al. Prognostic model based on nailfold capillaroscopy for identifying Raynaud's phenomenon patients at high risk for the development of a scleroderma spectrum disorder: PRINCE (Prognostic Index for Nailfold Capillaroscopic Examination). Arthritis Rheum 2008; 58: 217482.
  • 5
    Cutolo M, Matucci Cerinic M. Improving the sensitivity of the American College of Rheumatology classification criteria for systemic sclerosis. Clin Exp Rheumatol 2007; 25: 6635.
  • 6
    Bukhari M, Hollis S, Moore T, Jayson MI, Herrick AL. Quantitation of microcirculatory abnormalities in patients with primary Raynaud's phenomenon and systemic sclerosis by video-capillaroscopy. Rheumatology (Oxford) 2000; 39: 50612.
  • 7
    Anderson ME, Allen PD, Moore T, Hillier V, Taylor CJ, Herrick AL. Computerized nailfold video capillaroscopy: a new tool for assessment of Raynaud's phenomenon. J Rheumatol 2005; 32: 8418.
  • 8
    Grassi W, de Angelis R. Capillaroscopy: questions and answers. Clin Rheumatol 2007; 26: 200916.
  • 9
    Maricq HR, Spencer-Green G, LeRoy EC. Skin capillary abnormalities as indicators of organ involvement in scleroderma (systemic sclerosis), Raynaud's syndrome and dermatomyositis. Am J Med 1976; 61: 86270.
  • 10
    Simeon CP, Fonollosa V, Vilardell M, Armadans L, Lima J, Cuenca R, et al. Study of the capillary microscopy changes in scleroderma and their association with organ disease, clinical manifestation and disease progression. Med Clin (Barc) 1991; 97: 5614.
  • 11
    Thompson RP, Harper FE, Maize JC, Ainsworth SK, LeRoy EC, Maricq HR. Nailfold biopsy in scleroderma and related disorders: correlation of histologic, capillaroscopic, and clinical data. Arthritis Rheum 1984; 27: 97103.
  • 12
    Cutolo M, Sulli A, Secchi ME, Paolino S, Pizzorni C. Nailfold capillaroscopy is useful for the diagnosis and follow-up of autoimmune rheumatic diseases: a future tool for the analysis of microvascular heart involvement? Rheumatology (Oxford) 2006; 45 Suppl 4: iv436.
  • 13
    Ong YY, Nikoloutsopoulos T, Bond CP, Smith MD, Ahern MJ, Roberts-Thomson PJ. Decreased nailfold capillary density in limited scleroderma with pulmonary hypertension. Asian Pac J Allergy Immunol 1998; 16: 816.
  • 14
    Cutolo M, Pizzorni C, Tuccio M, Burroni A, Craviotto C, Basso M, et al. Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis. Rheumatology (Oxford) 2004; 43: 71926.
  • 15
    Caramaschi P, Canestrini S, Martinelli N, Volpe A, Pieropan S, Ferrari M, et al. Scleroderma patients nailfold videocapillaroscopic patterns are associated with disease subset and disease severity. Rheumatology (Oxford) 2007; 46: 15669.
  • 16
    Nihtyanova SI, Brough GM, Black CM, Denton CP. Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2008; 67: 1203.
  • 17
    Herrick A. Diagnosis and management of scleroderma peripheral vascular disease. Rheum Dis Clin North Am 2008; 34: 89114.
  • 18
    Mawdsley AH. Patient perception of UK scleroderma services: results of an anonymous questionnaire [letter]. Rheumatology (Oxford) 2006; 45: 1573.
  • 19
    Masi AT, Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 58190.
  • 20
    Maricq HR, Harper FE, Khan MM, Tan EM, LeRoy EC. Microvascular abnormalities as possible predictors of disease subsets in Raynaud phenomenon and early connective tissue disease. Clin Exp Rheumatol 1983; 1: 195205.
  • 21
    Lefford F, Edwards JC. Nailfold capillary microscopy in connective tissue disease: a quantitative morphological analysis. Ann Rheum Dis 1986; 45: 7419.
  • 22
    Bollinger A, Fagrell B. Clinical capillaroscopy: a guide to its use in clinical research and practice. Toronto: Hogrefe & Huber; 1990.
  • 23
    Grassi W, del Medico P. Atlas of capillaroscopy. 1st ed. Milan: Edra; 2004.
  • 24
    Dolezalova P, Young SP, Bacon PA, Southwood TR. Nailfold capillary microscopy in healthy children and in childhood rheumatic diseases: a prospective single blind observational study. Ann Rheum Dis 2003; 62: 4449.
  • 25
    Altman DG. Practical statistics for medical research. 1st ed. London: Chapman & Hall; 1991.
  • 26
    Lovy M, MacCarter D, Steigerwald JC. Relationship between nailfold capillary abnormalities and organ involvement in systemic sclerosis. Arthritis Rheum 1985; 28: 496501.
  • 27
    Statham BN, Rowell NR. Quantification of the nail fold capillary abnormalities in systemic sclerosis and Raynaud's syndrome. Acta Derm Venereol 1986; 66: 13943.
  • 28
    Schmidt KU, Mensing H. Are nailfold capillary changes indicators of organ involvement in progressive systemic sclerosis? Dermatologica 1988; 176: 1821.
  • 29
    Ohtsuka T, Hasegawa A, Nakano A, Yamakage A, Yamaguchi M, Miyachi Y. Nailfold capillary abnormality and pulmonary hypertension in systemic sclerosis. Int J Dermatol 1997; 36: 11622.
  • 30
    Pucinelli ML, Atra E, Sato EI, Andrade LE. Nailfold capillaroscopy in systemic sclerosis: correlations with involvement of lung and esophagus. Rev Bras Rheumatol 1995; 35: 13642.
  • 31
    Groen H, Wichers G, ter Borg EJ, van der Mark TW, Wouda AA, Kallenberg CG. Pulmonary diffusing capacity disturbances are related to nailfold capillaroscopy changes in patients with Raynaud's phenomenon with and without an underlying connective tissue disease. Am J Med 1990; 89: 3441.
  • 32
    Joyal F, Choquette D, Roussin A, Levington C, Senecal JC. Evaluation of severity of systemic sclerosis by nailfold capillary microscopy in 112 patients. Angiology 1992; 43: 20310.
  • 33
    Scheja A, Akesson A, Niewierowicz I, Wallin L, Wildt M, Wollheim FA. Computer based quantitative analysis of capillary abnormalities in systemic sclerosis and its relation to plasma concentration of von Willebrand factor. Ann Rheum Dis 1996; 55: 526.
  • 34
    Silver RM, Metcalf JF, Stanley JH, LeRoy EC. Interstitial lung disease in scleroderma: analysis by bronchoalveolar lavage. Arthritis Rheum 1984; 27: 125462.
  • 35
    Andrade LE, Gabriel A Jr, Assad RL, Ferrari AJ, Atra E. Panoramic nailfold capillaroscopy: a new reading method and normal range. Semin Arthritis Rheum 1990; 20: 2131.
  • 36
    Bredemeier M, Xavier RM, Capobianco KG, Restelli VG, Rohde LE, Pinotti AF, et al. Nailfold capillary microscopy can suggest pulmonary disease activity in systemic sclerosis. J Rheumatol 2004; 31: 28694.
  • 37
    Sulli A, Secchi ME, Pizzorni C, Cutolo M. Scoring the nailfold microvascular changes during the capillaroscopic analysis in systemic sclerosis patients. Ann Rheum Dis 2008; 67: 8857.
  • 38
    Aschwanden M, Daikeler T, Jaeger KA, Thalhammer C, Gratwohl A, Matucci-Cerinic M, et al. Rapid improvement of nailfold capillaroscopy after intense immunosuppression for systemic sclerosis and mixed connective tissue disease. Ann Rheum Dis 2008; 67: 10579.
  • 39
    Fleming JN, Nash RA, McLeod DO, Fiorentino DF, Shulman HM, Connolly MK, et al. Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS ONE 2008; 3: e1452.
  • 40
    Ingegnoli F, Gualtierotti R, Lubatti C, Zahalkova L, Meani L, Boracchi P, et al. Feasibility of different capillaroscopic measures for identifying nailfold microvascular alterations. Semin Arthritis Rheum 2009; 38: 28995.
  • 41
    Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 1992; 19: 140714.
  • 42
    Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004; 50: 398593.
  • 43
    Ferri C, Giuggioli D, Sebastiani M, Colaci M. Treatment of severe scleroderma skin ulcers with recombinant human erythropoietin. Clin Exp Dermatol 2007; 32: 28790.
  • 44
    Giuggioli D, Magistro R, Colaci M, Franciosi U, Caruso A, Ferri C. The treatment of skin ulcers in systemic sclerosis: use of granulocyte-colony stimulating factor (G-CSF) in 26 patients. Reumatismo 2006; 58: 2630. In Italian.
  • 45
    Chung L, Fiorentino D. A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis. J Am Acad Dermatol 2006; 545: 8802.
  • 46
    Faggioli P, Giani L, Mazzone A. Possible role of iloprost (stable analog of PG12) in promoting neoangiogenesis in systemic sclerosis [letter]. Clin Exp Rheumatol 2006; 24: 2201.
  • 47
    Della Bella S, Molteni M, Mocellin C, Fumagalli S, Bonara P, Scorza R. Novel mode of action of iloprost: in vitro down-regulation of endothelial cell adhesion molecules. Prostaglandins Other Lipid Mediat 2001; 65: 7383.
  • 48
    Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA Jr, et al. Intravenous iloprost infusion in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994; 120: 199206.
  • 49
    Tiso F, Favaro M, Ciprian L, Cardarelli S, Rizzo M, Tonello M, et al. Digital ulcers in a cohort of 333 scleroderma patients. Reumatismo 2007; 59: 21520. In Italian.
  • 50
    Chung L, Fiorentino D. Digital ulcers in patients with systemic sclerosis. Autoimmun Rev 2006; 5: 1258.